BaFin's Review of Eckert & Ziegler's 2024 Financial Statements

Berlin-based Eckert & Ziegler SE disclosed that the Federal Financial Supervisory Authority (BaFin) has started a special review of their 2024 consolidated financial statements. The scrutiny focuses on the spin-off of Pentixapharm AG in October 2024. BaFin is assessing whether off-balance-sheet write-offs of Pentixapharm's assets and liabilities were justified or if they should have been included in earnings. If recognized in earnings, this could yield additional profit from discontinued operations, yet without altering key operating figures or affecting future financial years.

The company maintains engaged communication with BaFin to address this issue. The outcome of this review could influence the representation of profits in their accounts but is not expected to impact the fundamental operational metrics or overall financial health of Eckert & Ziegler.